Search 

Welcome to the Center for Human Reproduction (CHR), a leading fertility center located in New York City. CHR is known as a “fertility center of last resort,” primarily serving patients who have previously failed treatments elsewhere. Among CHR’s areas of special expertise are treatments of “older” ovaries, whether due to advanced female age or premature ovarian aging (POA), immunological problems affecting reproduction, repeated pregnancy loss, endometriosis, polycystic ovary syndrome (PCOS), tubal disease, male factor infertility, etc.

Harnessing the brain’s immune system to fight neurodegeneration.

CereSpir is leading the way with a completely novel approach to Alzheimer’s disease (AD) by reducing inflammation and increasing clearance of tissue debris in the brain as a potential first disease-modifying treatment targeting the very earliest stages of the disease.

CSP-1103, an orally delivered tablet, has undergone Phase 2 testing in people with Mild Cognitive Impairment (MCI). The Company aims to initiate Phase 3 trials in 2015. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain.

Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening. Chromocell’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. In our flavors and nutrition business, Chromocell works with global consumer goods companies to discover and develop flavor ingredients and natural taste enhancers. The technology is applicable to all areas of taste sensations as well as aroma and fragrance enhancer discovery.

The Private Company Access team leverages Citigroup’s strength and expertise in Institutional Sales and Trading to assist emerging growth companies with their investor relations objectives.
• Institutional investors are increasingly looking for access to emerging growth companies for direct investments, as well as to better understand looming risks to the public companies they own
• Growth-oriented companies are staying private longer, but need access to capital from institutional-type sources

When it opens in the fall of 2014, the Advanced Science Research Center will bring CUNY to a landmark moment in its decade-long, multi-billion-dollar commitment to becoming a national leader in visionary scientific research of vital, real-world consequence.

A decade in the planning, the first phase of the ASRC is rapidly taking shape on the south end of the City College campus in Upper Manhattan: a striking glass-encased structure that will be at the center of CUNY’s expanding universe of science and embody a bold vision of 21st Century discovery.

The construction of a $350 million building with 200,000 square feet of world-class facilities would be big news for any institution, public or private. But sophistication and scale are only part of  the ASRC story. At the center’s core will be an innovative approach to the scientific method itself, one that seeks to break down some of the walls between disparate but increasingly inter-related disciplines of applied science.

The ASRC will focus CUNY initiatives in five of the most energized areas of global research: Nanoscience. Photonics. Structural Biology. Neuroscience. Environmental Sciences.

If you’ve been looking for something different from your CRO, choose the one that stands out.

Welcome to Clinilabs, where science leads business.

Clinilabs is a premier full-service CRO that specializes in applying scientific principles to phase I, II, and III studies in order to bring investigational products to the threshold of successful approval.  Our unique development strategy builds value into early phase development programs, carrying promising products forward swiftly and abandoning failures early.  We enable our clients to apply their resources wisely and maximize the value of their drug and device portfolios.
 
Expect something different from your CRO – Science. Communication. Collaboration. Results. 

ClinSmart is known as a trusted partner for both simple and comprehensive development programs required by biopharmaceutical and medical device companies, since 1994. Our academically and industry trained staff, combined and supported by the latest proven technologies, focuses on improving the efficiency of clinical development while minimizing risk and costs. We guarantee upfront strategic clinical planning, high quality regulatory packages including risk mitigation strategies prior to the start of any project, organizational structure which results in lower costs than a large CRO, global capabilities, and overall clinical and scientific expertise. Our experienced staff will work closely with your team to understand the requirements of your development program and will ensure that the right team is put into place to accomplish the tasks at hand.

For more information about our team and services, please visit our website (www.clinsmart.com) and LinkedIn page.